Biogen
Develops neurological medicines spanning MS, rare disease, Alzheimer’s, and complement-mediated conditions.
$218.19
After-hours close−0.30 (−0.14%)
At close$218.49(−1.36%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 129.06%Insiders 0.18%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 147.75M · Float 146.43M · 99.1% free float
Institutions13F, as of Jun 30, 2026
1,095 holders · 190.69M shares · 130 new positions · 554 increased · 294 reduced · 96 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 18.22M | 12.33% | +5.41M | Aug 13, 2026 |
| BlackRock, Inc. | 15.99M | 10.82% | +11.1K | Aug 7, 2026 |
| Primecap Management Co/CA/ | 15.15M | 10.26% | +397.0K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 9.65M | 6.53% | +113.7K | Aug 13, 2026 |
| State Street Corp | 7.34M | 4.97% | +176.4K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 6.60M | 4.47% | +73.2K | Aug 13, 2026 |
| Geode Capital Management, LLC | 4.45M | 3.01% | +106.7K | Aug 12, 2026 |
| Wellington Management Group LLP | 3.12M | 2.11% | +155.8K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 11.30% | 16.65M | 13G | Jun 5, 2026 ↗ |
| Primecap Management Co/CA/ | 10.20% | 14.95M | 13G | Nov 13, 2025 ↗ |
| BlackRock, Inc. | 8.50% | 12.51M | 13G | Apr 17, 2025 ↗ |
| Vanguard Capital Management | 7.48% | 10.99M | 13G | Apr 29, 2026 ↗ |
| State Street Corporation | 5.00% | 7.32M | 13G | Nov 10, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Susan H. Alexander | officer: EVP Chief Legal Officer | 57.5K | 0.04% | Feb 10, 2026 |
| Caroline Dorsa | director | 31.0K | 0.02% | Jun 18, 2025 |
| Eric K. Rowinsky | director | 25.8K | 0.02% | Jun 11, 2026 |
| Christopher Viehbacher | director, officer: President and CEO | 21.1K | 0.01% | Feb 10, 2026 |
| Nicole Murphy | officer: Head of Pharm Ops and Tech | 19.6K | 0.01% | Feb 17, 2026 |
| Ginger Gregory | officer: EVP, Human Resources | 18.6K | 0.01% | Feb 10, 2026 |
| Stephen A. Sherwin | director | 15.2K | 0.01% | Jun 11, 2026 |
| Jesus B. Mantas | director | 11.3K | 0.01% | Jun 11, 2026 |
| William A. Hawkins | director | 10.4K | 0.01% | Jun 11, 2026 |
| Maria C. Freire | director | 8.8K | 0.01% | Jun 11, 2026 |
43 people have not refiled in the last 18 months (1.02M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 4, 2026 | Lloyd Minordirector | Sale | 593 | $200.96 | 2,689 |
| Aug 3, 2026 | Lloyd Minordirector | Sale | 593 | $203.34 | 3,282 |
| Feb 12, 2026 | Nicole Murphyofficer: Head of Pharm Ops and Tech | Purchase | 3 | $195.04 | 19,611 |
| Feb 9, 2026 | Priya Singhalofficer: Head of Development | Sale | 2,660 | $199.83 | 8,043 |
| Feb 2, 2026 | Priya Singhalofficer: Head of Development | Sale | 748 | $179.30 | 6,271 |
| Sep 2, 2025 | Priya Singhalofficer: Head of Development | Sale | 517 | $133.55 | 5,772 |
CongressHouse and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Maria Elvira Salazar · FL27 | Sale | $15,001 – $50,000 | Jun 2, 2026 | Jul 8, 2026 ↗ | |
| Rep. Gilbert Cisneros · CA31 | Purchase | $1,001 – $15,000 | Jun 5, 2026 | Jul 3, 2026 ↗ | |
| Rep. Maria Elvira Salazar · FL27 | Purchase | $1,001 – $15,000 | May 12, 2026 | Jun 9, 2026 ↗ | |
| Rep. Maria Elvira Salazar · FL27 | Purchase | $50,001 – $100,000 | May 11, 2026 | Jun 9, 2026 ↗ | |
| Rep. Maria Elvira Salazar · FL27 | Purchase | $1,001 – $15,000 | May 11, 2026 | Jun 9, 2026 ↗ |